Docetaxel in the management of ovarian cancer

References

• Guastalla JP III, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br. J. Cancer 89(Suppl. 3), S16–S22 (2003).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Paul J, Birt A et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J. Clin. Oncol. 17, 2069–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In: Cancer: Principles and Practice of Oncology, 4th edition. deVita VT, Hellman S, Rosenberg SA (Eds), JB Lippincott Co., PA, USA, 1226–1263 (1993).
   Google Scholar
• Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J. Clin. Oncol. 18(14), 2733–2739 (2000).
   PubMed Web of Science ®Google Scholar
• New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46(1), 108–111 (1996).
   PubMed Web of Science ®Google Scholar
• Cragg GM, Boyd MR, Cardellina JH II, Newman DJ, Snader KM, McCloud TG. Ethnobotany and drug discovery: the experience of the US National Cancer Institute. CIBA Found. Symp. 185, 178–190 (1994).
   PubMedGoogle Scholar
• Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 277(5698), 665–667 (1980).
   Google Scholar
• Denis JN, Correa A, Greene AE. An improved synthesis of the Taxol side chain and of RP 56976. J. Org. Chem. 55, 1957–1959 (1990).
   Web of Science ®Google Scholar
• Mastropaolo D, Camerman A, Luo Y, Brayer GD, Camerman N. Crystal and molecular structure of paclitaxel (Taxol). Proc. Natl Acad. Sci. USA 92, 6920–6924 (1995).
   PubMed Web of Science ®Google Scholar
• Lam YW, Chan CY, Kuhn JG. Pharmacokinetics and pharmacodynamics of the taxanes. J. Clin. Pharm. Pract. 3, 76–93 (1997).
   Google Scholar
• Hanauske AR, Degen D, Hilsenbeck SG et al. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3, 121–124 (1992).
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4(4), 253–265 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia P, Braguer D, Carles G et al. Comparative effects of Taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother. Pharmacol. 34(4), 335–343 (1994).
   PubMed Web of Science ®Google Scholar
• Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl Cancer Inst. 83(4), 288–291 (1991).
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17(3), 1061–1070 (1999).
   PubMed Web of Science ®Google Scholar
• Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer 71(6), 1194–1198 (1995).
   PubMedGoogle Scholar
• Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem. Rec. 1(3), 195–211 (2001).
   PubMed Web of Science ®Google Scholar
• Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl. 2), 3–8 (2004).
   PubMed Web of Science ®Google Scholar
• Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of anti-angiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere) Int. J. Cancer 104, 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl Acad. Sci. USA 95(7), 3896–3901 (1998).
   PubMed Web of Science ®Google Scholar
• Rigas JR. Taxane–platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9(Suppl. 2), 16–23 (2004).
   PubMed Web of Science ®Google Scholar
• Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR co-ordinately regulates drug metabolism and efflux. Nature Med. 7(5), 584–590. (2001).
   PubMed Web of Science ®Google Scholar
• Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 53(5), 1037–1042 (1993).
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 81(2), 330–335 (1999).
   PubMed Web of Science ®Google Scholar
• Riou JF, Petitgenet O, Combeau C et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc. Am. Assoc. Cancer Res. 35, 385 (1994) (Abstract 2292).
   Google Scholar
• Pazdur R, Newman RA, Newman BA et al. Phase I trial of Taxotere: five-day schedule. J. Natl Cancer Inst. 84(23), 1781–1786 (1992).
   PubMedGoogle Scholar
• de Valeriola D, Brassinne C, Piccart M et al. Phase I and pharmacokinetic study of Taxotere as a weekly infusion. Proc. Am. Assoc. Cancer Res. 33, 261 (1992).
   Google Scholar
• Cortes JE, Pazdur R. Docetaxel. J. Clin. Oncol. 13, 2643–2655 (1995).
   PubMed Web of Science ®Google Scholar
• Burris H, Irvin R, Kuhn J et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol. 11(5), 950–958 (1993).
   PubMedGoogle Scholar
• Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 53(3), 523–527 (1993).
   PubMed Web of Science ®Google Scholar
• Hong WK. The current status of docetaxel in solid tumors. An MD Anderson Cancer Center Review. Oncology (Huntingt.) 16(6 Suppl. 6), 9–15 (2002).
   PubMedGoogle Scholar
• Ravdin P, Erban J, Overmoyer B et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur. J. Cancer 1(Suppl. 5), S201 (2003).
   Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a Phase III randomized trial in patients with sub optimal Stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23(5 Suppl. 12), 40–47 (1996).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92(9), 699–708 (2000).
   PubMed Web of Science ®Google Scholar
• Muggia FM, Braly PS, Brady MF et al. Phase III randomised study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal Stage III or IV ovarian cancer: a Gynaecologic Oncology Group study. J. Clin. Oncol. 18, 106–115 (2000).
   PubMed Web of Science ®Google Scholar
• Harper P, on behalf of the ICON Collaborators. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the third International Collaborative Ovarian Neoplasm Study (ICON3). Proc. Am. Soc. Clin. Oncol. 18, 356a (1999) (Abstract 1375).
   Google Scholar
• Colombo N. Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): the Third International Collaborative Ovarian Neoplasm Study (ICON3). Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 1500).
   PubMedGoogle Scholar
• Sandercock J, Parmar MKB, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 87, 815–824 (2002).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 4(5), 1087–1100 (1998).
   PubMed Web of Science ®Google Scholar
• Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J. Urol. 20(3), 158–166 (2002).
   PubMed Web of Science ®Google Scholar
• Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists’ Group. Br. J. Cancer 78(11), 1479–1487(1998).
   PubMed Web of Science ®Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18(17), 3084–3092 (2000).
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Von Hoff DD. Taxol: a new and effective anticancer drug. Anticancer Drugs 2(6), 519–530 (1991).
   PubMed Web of Science ®Google Scholar
• McNally OM, Delaney E, Petty RD, Cruickshank ME, Hutcheon AW, Parkin DE. Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. Br. J. Cancer 89(6), 966–967 (2003).
   PubMedGoogle Scholar
• Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8(10), 963–968 (1997).
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375), 2099–2106 (2003).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a gynaecologic cancer intergroup randomized Phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc. Am. Soc. Clin. Oncol. 22(14S) (2004) (Abstract 5005).
   Google Scholar
• Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer – treatment of recurrent disease. Lancet Oncol. 3(9), 537–545 (2002).
   PubMed Web of Science ®Google Scholar
• Kaern J, Baekelandt M, Trope CG. A Phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur. J. Gynaecol. Oncol. 23(5), 383–389 (2002).
   PubMed Web of Science ®Google Scholar
• Aapro M, Bruno R. Early clinical studies with docetaxel. Docetaxel Investigators Group. Eur. J. Cancer 31A(Suppl. 4), S7–S10 (1995).
   Google Scholar
• Piccart MJ, Gore M, Ten Bokkel Huinink W et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Natl Cancer Inst. 87(9), 676–681 (1995).
   PubMed Web of Science ®Google Scholar
• Francis P, Schneider J, Hann L et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12(11), 2301–2308 (1994).
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. 2(5), 837–842 (1996).
   PubMed Web of Science ®Google Scholar
• Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer – an updated overview. Eur. J. Cancer 33, 2167–2170 (1997).
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Wanders J, Dirix L et al. Coping with toxicities of docetaxel (Taxotere). Ann. Oncol. 4(7), 610–611 (1993).
   PubMed Web of Science ®Google Scholar
• Kaye SB, Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int. J. Gynaecol. Cancer 11, 31–33 (2001).
   Google Scholar
• Dieras V, Guastalla JP, Ferrero JM et al. A multicenter Phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study. Cancer Chemother. Pharmacol. 53(6), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Atkinson R, Coleman R et al. Docetaxel–carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. J. Cancer 84(2), 170–178 (2001).
   PubMed Web of Science ®Google Scholar
• Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur. J. Cancer 36(6), 766–771 (2000).
   PubMedGoogle Scholar
• Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am. J. Clin. Oncol. 27(1), 14–18 (2004).
   PubMedGoogle Scholar
• Rustin GJ, Atkinson RA, Osborne R et al. Preliminary results of SCOTROC 2A, a randomised feasibility study of carboplatin (C) then sequential docetaxel (D) or two schedules of docetaxel + gemcitabine (G) in ovarian/Müllerian cancers Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 810).
   Google Scholar
• Vasey P, Atkinson R, Osborne R et al. Carboplatin (Cb) followed sequentially by docetaxel (D) ± gemcitabine (G) in ovarian, peritoneal and fallopian tube cancers. Results of SCOTROC 2A. Proc. Am. Soc. Clin. Oncol. 22(449) (2003) (Abstract 1804).
   Google Scholar
• Jayson GC, Maenpaa J, Wilkinson PM et al. Randomized feasibility study of carboplatin followed by docetaxel or docetaxel/irinotecan in ovarian cancer (SCOTROC IIB). Proc. Am. Soc. Clin. Oncol. 22(449) (2003) (Abstract 1805).
   Google Scholar
• Agarwal R, Kaye S, Vasey P et al. Erlotinib (E) in combination with docetaxel (D) and carboplatin (C): a Phase Ib trial in patients with untreated ovarian, fallopian tube and primary peritoneal cancers. Ann. Oncol. 15(20) (2004) (Abstract 475).
   Google Scholar
• Untch M, Untch A, Sevin BU et al. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 5(1), 24–30 (1994).
   PubMed Web of Science ®Google Scholar
• Valero V, Jones SE, Von Hoff DD et al. A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 16(10), 3362–3368 (1998).
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Ball HG et al. A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynaecologic Oncology Group study. Gynaecol. Oncol. 88(2), 130–135 (2003).
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Winn R, Steger M et al. Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update. Proc. Am. Soc. Clin. Oncol. 18, 368a (1999) (Abstract 1423).
   Google Scholar
• Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J. Clin. Oncol. 18, 2733–2739 (2000).
   PubMed Web of Science ®Google Scholar
• Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome cYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6(4), 1255–1258 (2000).
   PubMed Web of Science ®Google Scholar
• McNeil C. Herceptin raises its sights beyond advanced breast cancer. J. Natl Cancer Inst. 90(12), 882–883 (1998).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol. 27(6 Suppl. 11), 21–25 (2000).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized antiHER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(2), 283–290 (2003).
   PubMed Web of Science ®Google Scholar
• Chatta GS, Fakih M, Ramalingam S et al. Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 2047).
   Google Scholar
• Overmoyer B, Silverman P, Leeming R et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 727).
   Google Scholar
• Forero L, Patnaik A, Hammond LA et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1908).
   Google Scholar
• Reid T, Weeks A, Vakil M et al. Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 7279).
   Google Scholar
• Messersmith WA, Baker SD, Dinh K et al. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 3052).
   Google Scholar
• Rathkopf D, Fornier M, Shah M et al. A Phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 3072).
   Google Scholar
• Pietras K, Stumm M, Hubert M et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9(10 Pt 1), 3779–3787 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Uehara H, Yazici S et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res. 64(12), 4201–4208 (2004).
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 22(6), 375–387 (2004).
   PubMed Web of Science ®Google Scholar
• Roila F, Cortesi E. Quality of life as a primary end point in oncology. Ann. Oncol. 12(Suppl. 3), S3–S6 (2001).
   PubMed Web of Science ®Google Scholar
• Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 51(6), 1075–1092 (1996).
   PubMed Web of Science ®Google Scholar
• Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 8(2), 187–190 (1997).
   PubMedGoogle Scholar
• Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15), 1549–1563 (2003).
   PubMed Web of Science ®Google Scholar
• Rose PG, Smrekar M. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol. Oncol. 91(2), 423–425 (2003).
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 11(1), 82–85 (2004).
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Cull A, Howat S, Greimel E et al. Development of a European organisation for research and treatment of cancer questionnaire module to address the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur. J. Cancer 37, 47–53 (2001).
   PubMed Web of Science ®Google Scholar